Lakeshore Biopharma (LSB) Competitors

$0.44

0.00 (0.00%)

(As of 09/6/2024 ET)

Stock Analysis Chart Competitors Earnings Financials SEC Filings Short Interest Trends

LSB vs. DMAC, ZURA, CGEN, BIVI, MDWD, ACTU, VXRT, GBIO, FTLF, and PRQR

Should you be buying Lakeshore Biopharma stock or one of its competitors? The main competitors of Lakeshore Biopharma include DiaMedica Therapeutics (DMAC), Zura Bio (ZURA), Compugen (CGEN), BioVie (BIVI), MediWound (MDWD), Actuate Therapeutics (ACTU), Vaxart (VXRT), Generation Bio (GBIO), FitLife Brands (FTLF), and ProQR Therapeutics (PRQR). These companies are all part of the "pharmaceutical products" industry.

Lakeshore Biopharma vs.

DiaMedica Therapeutics (NASDAQ:DMAC) and Lakeshore Biopharma (NASDAQ:LSB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

: DiaMedica Therapeutics has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, Lakeshore Biopharma has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.
: DiaMedica Therapeutics presently has a consensus target price of $7.00, suggesting a potential upside of 73.70%. Given DiaMedica Therapeutics' higher possible upside, equities analysts clearly believe DiaMedica Therapeutics is more favorable than Lakeshore Biopharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DiaMedica Therapeutics
0 Sell rating(s)
0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
3.00
Lakeshore Biopharma
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
: In the previous week, Lakeshore Biopharma had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 2 mentions for Lakeshore Biopharma and 1 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.00 equaled Lakeshore Biopharma'saverage media sentiment score.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DiaMedica Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Lakeshore Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: DiaMedica Therapeutics has higher earnings, but lower revenue than Lakeshore Biopharma.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
DiaMedica Therapeutics N/A N/A -$19.38M -$0.56 -7.20
Lakeshore Biopharma $80.82M 0.51 -$61.09M N/A N/A
: 10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 52.6% of Lakeshore Biopharma shares are owned by institutional investors. 7.2% of DiaMedica Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
: Lakeshore Biopharma's return on equity of 0.00% beat DiaMedica Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
DiaMedica Therapeutics N/A -38.56% -36.46%
Lakeshore Biopharma N/A N/A N/A
: DiaMedica Therapeutics received 91 more outperform votes than Lakeshore Biopharma when rated by MarketBeat users.
Company Underperform Outperform
DiaMedica Therapeutics Outperform Votes
91
62.33%
Underperform Votes
55
37.67%
Lakeshore Biopharma N/A N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Lakeshore Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DiaMedica Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lakeshore Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$19.38M	-$0.56	-7.20
Lakeshore Biopharma	$80.82M	0.51	-$61.09M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-38.56%	-36.46%
Lakeshore Biopharma	N/A	N/A	N/A

Company	Underperform	Outperform
DiaMedica Therapeutics	Outperform Votes 91 62.33%	Underperform Votes 55 37.67%
Lakeshore Biopharma	N/A	N/A

Summary

DiaMedica Therapeutics beats Lakeshore Biopharma on 6 of the 11 factors compared between the two stocks.

Ad Deal Maker

The solution to fast food’s wage hike crisis

Shake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.

Learn more about this much-needed advancement and investment opportunity here.

Get Lakeshore Biopharma News Delivered to You Automatically

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LSB vs. The Competition

Export to Excel

Metric	Lakeshore Biopharma	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$43.74M	$7.67B	$5.69B	$7.88B
Dividend Yield	N/A	2.69%	2.73%	4.03%
P/E Ratio	N/A	18.83	112.46	17.85
Price / Sales	0.51	303.82	1,774.85	79.14
Price / Cash	N/A	36.94	38.83	32.58
Price / Book	0.50	6.17	4.97	4.44
Net Income	-$61.09M	$147.59M	$114.73M	$224.46M
7 Day Performance	N/A	0.15%	-1.52%	-3.60%
1 Month Performance	9.68%	17.12%	8.47%	5.28%
1 Year Performance	N/A	12.12%	12.47%	4.44%

Lakeshore Biopharma Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DMAC DiaMedica Therapeutics	1.7814 of 5 stars 1.78 / 5 stars	$3.85 -2.8%	$7.00 +81.8%	+19.2%	$164.56M	N/A	-6.87	20	News Coverage
ZURA Zura Bio	1.1546 of 5 stars 1.15 / 5 stars	$3.77 -4.6%	$15.50 +311.1%	-48.1%	$164.35M	N/A	0.00	3	Analyst Forecast Insider Selling Analyst Revision News Coverage
CGEN Compugen	0.5842 of 5 stars 0.58 / 5 stars	$1.82 -7.6%	$4.00 +119.8%	+69.4%	$162.42M	$42.72M	-9.58	70	Positive News
BIVI BioVie	1.4825 of 5 stars 1.48 / 5 stars	$2.63 -0.8%	$4.00 +52.1%	-25.2%	$160.87M	N/A	-2.80	10	Upcoming Earnings
MDWD MediWound	1.0596 of 5 stars 1.06 / 5 stars	$17.20 +1.2%	$29.00 +68.6%	+115.6%	$159.69M	$20.14M	-12.46	80
ACTU Actuate Therapeutics	0 of 5 stars 0.00 / 5 stars	$8.15 -0.5%	N/A	N/A	$155.75M	N/A	54.33	10	Positive News
VXRT Vaxart	2.2545 of 5 stars 2.25 / 5 stars	$0.88 +2.3%	$3.33 +278.5%	+10.7%	$155.72M	$15.65M	-1.66	120	Gap Down
GBIO Generation Bio	1.3371 of 5 stars 1.34 / 5 stars	$2.32 -0.4%	$7.50 +223.3%	-54.2%	$154.35M	$13.17M	-0.91	150
FTLF FitLife Brands	2.8873 of 5 stars 2.89 / 5 stars	$33.45 +0.8%	$40.00 +19.6%	+93.4%	$153.80M	$60.68M	22.60	20	Analyst Forecast Analyst Revision News Coverage
PRQR ProQR Therapeutics	0.6677 of 5 stars 0.67 / 5 stars	$1.89 -0.5%	$3.38 +79.0%	+16.7%	$153.35M	$15.41M	-5.09	180	Positive News